)
Andrew represents clients in intellectual property matters—principally for clients in the pharmaceutical, chemical, and biotechnology industries. His practice is varied, though it often allows him to utilize the technical training he received while earning his Ph.D. in Medicinal Chemistry & Molecular Pharmacology for research on the synthesis and biological evaluation of small molecule therapeutics.
Andrew regularly litigates matters brought under the Hatch-Waxman Act and counsels clients as they prepare their Abbreviated New Drug Applications (ANDAs). He also represents both patent owners and petitioners in administrative proceedings before the Patent Trial and Appeal Board (PTAB). And when he isn’t preparing for trial, Andrew helps clients obtain patents, analyzes third-party patents, conducts due diligence studies, and prepares opinions on patent-related issues.
In his free time, Andrew enjoys hiking, camping, and mastering the art of home brewing.
Clerk Experience
From 2017 to 2019, Andrew served as a judicial law clerk for the Honorable Pauline Newman of the U.S. Court of Appeals for the Federal Circuit—the appellate court hearing all patent appeals coming out of district courts, the United States Patent and Trademark Office, and the ITC.
- Named to the Best Lawyers: Ones to Watch guide, which “recognizes lawyers who are earlier in their careers for their outstanding professional excellence in private practice”, for Intellectual Property Litigation (2021 - 2022)
N. Nenortas, M. Cinelli, A. Morrell, M. Cushman, & T. Shapiro, “Activity of Aromathecins Against African Trypanosomes,” Antimicrob. Agents Chemother. 2018, 62, e00786–18.
M. Conda-Sheridan, P. V. Narasimha Reddy, A. Morrell, B. T. Cobb, C. Marchand, K. Agama, A. Chergui, A. Renaud, A. G. Stephen, L. K. Bindu, Y. Pommier, & M. Cushman, “Synthesis and Biological Evaluation of Indenoisoquinolines That Inhibit Both Tyrosyl-DNA Phosphodiesterase I (Tdp1) and Topoisomerase I (Top1),” J. Med. Chem. 2013, 56, 182-200.
L. Chen, M. Conda-Sheridan, P. V. N. Reddy, A. Morrell, E.-J. Park, T. P. Kondratyuk, J. M. Pezzuto, R. B. van Breemen, & M. Cushman, “Identification, Synthesis, and Biological Evaluation of the Metabolites of 3-Amino-6-(3'-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-dione (AM6-36), a Promising Rexinoid Lead Compound for the Development of Cancer Chemotherapeutic and Chemopreventive Agents,” J. Med. Chem. 2012, 55, 5965–81.
T. X. Nguyen, A. Morrell, M. Conda-Sheridan, C. Marchand, K. Agama, A. Bermingham, A. G. Stephen, A. Chergui, A. Naumova, R. Fisher, B. O’Keefe, Y. Pommier, & M. Cushman, “Synthesis and Biological Evaluation of the First Dual Tyrosyl-DNA Phosphodiesterase I (Tdp1)−Topoisomerase I (Top1) Inhibitors,” J. Med. Chem. 2012, 55, 4457–78.
E. Kiselev, S. DeGuire, A. Morrell, K. Agama, T. S. Dexheimer, Y. Pommier, & M. Cushman, “7-Azaindenoisoquinolines as Topoisomerase I Inhibitors and Potential Anticancer Agents,” J. Med. Chem. 2011, 54, 6106–16.
K. E. Peterson, M. A. Cinelli, A. E. Morrell, A. Mehta, T. S. Dexheimer, K. Agama, S. Antony, Y. Pommier, & M. Cushman, “Alcohol-, Diol-, and Carbohydrate-Substituted Indenoisoquinolines as Topoisomerase I Inhibitors: Investigating the Relationships Involving Stereochemistry, Hydrogen Bonding, and Biological Activity,” J. Med. Chem. 2011, 54, 4937–53.
E.-J. Park, T. P. Kondratyuk, A. Morrell, E. Kiselev, M. Conda-Sheridan, M. Cushman, S. Ahn, Y. Cho, J. J. White, R. B. van Breemen, & J. M. Pezzuto, “Induction of Retinoid X Receptor Activity and Consequent Up-regulation of p21WAF1/CIP1 by Indenoisoquinolines in MCF7 Cells,” Cancer Prev. Res. 2011, 4, 592–607.
L. Marler, M. Conda-Sheridan, M. A. Cinelli, A. E. Morrell, M. Cushman, L. Chen, K. Huang, R. van Breemen, & J. M. Pezzuto, “Cancer Chemopreventive Potential of Aromathecins and Phenazines, Novel Natural Product Derivatives,” Anticancer Res. 2010, 30, 4873–82.
M. A. Cinelli, A. E. Morrell, T. S. Dexheimer, K. Agama, S. Agrawal, Y. Pommier, & M. Cushman, “The Structure–activity Relationships of A-Ring-substituted Aromathecin Topoisomerase I Inhibitors Strongly Support a Camptothecin-like Binding Mode,” Bioorg. Med. Chem. 2010, 18, 5535–52.
R. P. Bakshi, D. Sang, A. Morrell, M. Cushman, & T. A. Shapiro, “Activity of Indenoisoquinolines against African Trypanosomes,” Antimicrob. Agents Chemother. 2009, 53, 123–28.
M. A. Cinelli, A. Morrell, T. S. Dexheimer, E. S. Scher, Y. Pommier, & M. Cushman, “Design, Synthesis, and Biological Evaluation of 14-Substituted Aromathecins as Topoisomerase I Inhibitors,” J. Med. Chem. 2008, 51, 4609–19.
S. Antony, K. K. Agama, Z.-H. Miao, K. Takagi, M. H. Wright, A. I. Robles, L. Varticovski, M. Nagarajan, A. Morrell, M., Cushman, & Y. Pommier, “Novel Indenoisoquinolines NSC 725776 and NSC 724998 Produce Persistent Topoisomerase I Cleavage Complexes and Overcome Multidrug Resistance,” Cancer Res. 2007, 67, 10397–405.
A. Morrell, S. Antony, G. Kohlhagen, Y. Pommier, & M. Cushman, “Nitrated Indenoisoquinolines as Topoisomerase I Inhibitors: A Systematic Study and Optimization,” J. Med. Chem. 2007, 50, 4419–30.
A. Morrell, M. Placzek, S. Parmley, S. Antony, T. Dexheimer, Y. Pommier & M. Cushman, “Optimization of the Indenone Ring of Indenoisoquinoline Topoisomerase I Inhibitors,” J. Med. Chem. 2007, 50, 4388–404.
A. Morrell, M. S. Placzek, J. D. Steffen, S. Antony, K. Agama, Y. Pommier, & M. Cushman, “Investigation of the Lactam Side Chain Length Necessary for Optimal Indenoisoquinoline Topoisomerase I Inhibition and Cytotoxicity in Human Cancer Cell Cultures,” J. Med. Chem. 2007, 50, 2040–48.
A. Morrell, S. Antony, G. Kohlhagen, Y. Pommier, & M. Cushman, “A Systematic Study of Nitrated Indenoisoquinolines Reveals a Potent Topoisomerase I Inhibitor,” J. Med. Chem. 2006, 49, 7740–53.
M. Nagarajan, A. Morrell, A. Ioanoviciu, S. Antony, G. Kohlhagen. M. Hollingshead, Y. Pommier, & M. Cushman, “Synthesis and Evaluation of Indenoisoquinoline Topoisomerase I Inhibitors Substituted with Nitrogen Heterocycles,” J. Med. Chem. 2006, 49, 6283–89.
X. Xiao, A. Morrell, P. E. Fanwick, & M. Cushman, “On the Mechanism of Conversion of 4-Carboxy-3,4-dihydro-3-phenyl-1(2H)-isoquinolones to Indeno[1,2-c]isoquinolines by Thionyl Chloride,” Tetrahedron 2006, 62, 9705–12.
M. Nagarajan, A. Morrell, S. Antony, G. Kohlhagen, K. Agama, Y. Pommier, P. A. Ragazzon, N. C. Garbett, J. B. Chaires, M. Hollingshead, & M. Cushman, “Synthesis and Biological Evaluation of Bisindenoisoquinolines as Topoisomerase I Inhibitors,” J. Med. Chem. 2006, 49, 5129–40.
S. Antony, K. K. Agama, Z.-H. Miao, M. Hollingshead, S. L. Holbeck, M. H. Wright, L. Varticovski, M. Nagarajan, A. Morrell, M. Cushman, & Y. Pommier, “Bisindenoisoquinoline Bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA Intercalator and Topoisomerase Inhibitor with Antitumor Activity,” Mol. Pharmacol. 2006, 70, 1109–20.
A. Morrell, M. Jayaraman, M. Nagarajan, B. M. Fox, M. R. Meckley, A. Ioanoviciu, Y. Pommier, S. Antony, M. Hollingshead, & M. Cushman, “Evaluation of Indenoisoquinoline Topoisomerase I Inhibitors Using a Hollow Fiber Assay,” Bioorg. Med. Chem. Lett. 2006, 16, 4395–99.
A. Morrell, S. Antony, G. Kohlhagen, Y. Pommier & M. Cushman, “Synthesis of Benz[d]indeno[1,2-b]pyran-5,11-diones: Versatile Intermediates for the Design and Synthesis of Topoisomerase I Inhibitors,” Bioorg. Med. Chem. Lett. 2006, 16, 1846–49.
Muthukaman Nagarajan, Andrew Morrell, Brian C. Fort, Marintha Rae Meckley, Smitha Antony, Glenda Kohlhagen, Yves Pommier, & Mark Cushman, “Synthesis and Anticancer Activity of Simplified Indenoisoquinoline Topoisomerase I Inhibitors Lacking Substituents on the Aromatic Rings,” J. Med. Chem. 2004, 47(23), 5651–61.
A. Morrell, S. Antony, G. Kohlhagen, Y. Pommier, & M. Cushman, “Synthesis of Nitrated Indenoisoquinolines as Topoisomerase I Inhibitors,” Bioorg. Med. Chem. Lett. 2004, 14, 3659–63.
Litigation Blog
- Venue and Pleading Infringement in Hatch-Waxman Litigation Turn on Location and Identity of ANDA Filer
- IPR Proceedings Were Not Prohibited by a Forum Selection Clause in a Non-disclosure Agreement
- Forget About Seeking a Reasonably Royalty—Court Affirms Order Excluding Damages Theory for Flash Memory Patent
- Billion Dollar Verdict Erased by Inadequate Description of Functional Claims
- Ineffective Skinny Label Leaves Generic Liable Despite Effort to Carve-Out the Patented Indication
- Not so fast—the PTAB must provide notice and opportunity for litigants to respond to sua sponte decisions
- Court Grants Relief From Judgment After Witness Lies About the Bed of Its Own Making
- Innovative Data Processing Is an Ineligible Algorithm
- Evidence Supports Prior Art’s Public Accessibility but Not the Board’s Adoption of an Unpresented Theory of Anticipation
- Patent Owner Arguments Do Not Limit the Scope of the Issues the Board May Address in Its Final Written Decision
- $5 Million Attorneys’ Fee Award Affirmed Because Government’s Litigation Position Not Substantially Justified
- Pre-Complaint Damages for Willful Infringement Sunk by Failure to Comply With Marking Statute
- IPR Time Bar Dispute over Timing of Service of Complaint Torpedoed on Appeal